Zhou, M; Mok, M T S; Sun, H; Chan, A W; Huang, Y; Cheng, A S L; Xu, G (2017). The anti-diabetic drug exenatide, a glucagon-like peptide-1 receptor agonist, counteracts hepatocarcinogenesis through cAMP–PKA–EGFR–STAT3 axis. Oncogene, (), –.
doi:10.1038/onc.2017.38
url to share this paper:
An interview with Sci-Hub Founder Alexandra Elbakyan Who exactly should pay for academic research